Results 41 to 50 of about 112,964 (206)

Development of taxane resistance in a panel of human lung cancer cell lines [PDF]

, 2008
Using a selection process designed to reflect clinically relevant conditions, a panel of taxane-selected variants were developed to study further the mechanisms of resistance in lung cancer.
Keenan, Joanne, Breen, Laura, Murphy, Lisa, Clynes, Martin   +3 more
core   +1 more source

Glutathione S‐transferase omega class 1 (GSTO1)‐associated large extracellular vesicles are involved in tumor‐associated macrophage‐mediated cisplatin resistance in bladder cancer

Molecular Oncology
Bladder cancer poses a significant challenge to chemotherapy due to its resistance to cisplatin, especially at advanced stages. Understanding the mechanisms behind cisplatin resistance is crucial for improving cancer therapy.
Yi‐Cheng Pan, Pei‐Yi Chu, Ching‐Chan Lin, Ching‐Yun Hsieh, Wei‐Yu Hsu, Lie‐Fen Shyur, Juan‐Cheng Yang, Wei‐Chao Chang, Yang‐Chang Wu   +8 more
doaj   +1 more source

SERBP1 is required for efficient HR repair and cisplatin chemoresistance in lung adenocarcinoma

Cell Death Discovery
Resistance to cisplatin limits its clinical efficacy in LUAD patients and leads to poor prognosis. SERPINE1 mRNA binding protein 1 (SERBP1), an RNA-binding protein, is associated with tumorigenesis and progression. However, its specific role in cisplatin
Yifei Xie, Qiongju Chen, Nana Tang, Yuanyuan Zeng, Jian Zhao, Yang Yang, Chang Li, Jianjun Li, Jianjie Zhu, Jian-an Huang, Zeyi Liu   +10 more
doaj   +1 more source

VANGL2 downregulates HINT1 to inhibit the ATM-p53 pathway and promote cisplatin resistance in small cell lung cancer

Cell Death Discovery
Cisplatin is a first-line drug for the treatment of small cell lung cancer (SCLC). Although the majority of patients with SCLC initially respond to cisplatin therapy, cisplatin resistance readily develops, leading to tumor progression.
Jiayi Xie, Huiying Liu, Chunqian Yang, Weitao Shen, Jian Zhang   +4 more
doaj   +1 more source

Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy [PDF]

, 2014
BRCA1, a key factor in homologous recombination repair may also regulate base excision repair (BER). Targeting BRCA1-BER deficient cells by blockade of ATM and DNA-PKcs could be a promising strategy in breast cancer.
Seedhouse, Claire, Russell, R, Moseley, P, Arora, A., Agarwal, D., Russell, R., Chan, Stephen, Green, A, Albarakati, N, Rakha, E.A., Abdel-Fatah, TMA, Caldas, C, Ellis, IO, Moseley, P., Rakha, Emad A., Albarakati, Nada, Doherty, Rachel, Chan, S., Perry, Christina, Seedhouse, C, Alsubhi, N., Ball, G., Moseley, Paul, Agarwal, D, Perry, C., Arora, Arvind, Alsubhi, N, Doherty, R, Arora, A, Russell, Roslin, Ball, G, Albarakati, N., Green, Andrew, Ball, Graham, Abdel-Fatah, Tarek M.A., Rakha, EA, Caldas, Carlos, Caldas, C., Ellis, I.O., Alsubhi, Nouf, Agarwal, Devika, Abdel-Fatah, T.M.A., Seedhouse, C., Chan, S, Doherty, R., Madhusudan, Srinivasan, Perry, C, Madhusudan, S, Green, A., Madhusudan, S., Ellis, Ian O.   +50 more
core   +1 more source

Research Progress of DNA Methylation in Cisplatin Resistance in Lung Cancer

Chinese Journal of Lung Cancer, 2023
As one of the most common malignant tumors, lung cancer poses a serious threat to human life and health. The platinum-based drug cisplatin (DDP) is used as the first-line treatment for lung cancer.
Jinzhe SUN, Jun CHEN
doaj   +1 more source

Long non-coding RNAs MACC1-AS1 and FOXD2-AS1 mediate NSD2-induced cisplatin resistance in esophageal squamous cell carcinoma

Molecular Therapy: Nucleic Acids, 2021
The nuclear receptor-binding SET domain (NSD) protein family encoding histone lysine methyltransferases is involved in cancer progression. However, the role of NSDs in esophageal squamous cell carcinoma (ESCC) remains unclear.
Wenhua Xue, Zhibo Shen, Lifeng Li, Yuanyuan Zheng, Dan Yan, Quancheng Kan, Jie Zhao   +6 more
doaj   +1 more source

Clinical resistance to platinum chemotherapy in ovarian cancer [PDF]

, 2009
Platinum drugs are the most active agents in ovarian cancer. Their cytotoxicty results from DNA crosslinking. High tumour response rates are seen, but 80 % of patients relapse. Major mechanisms of platinum resistance in patients remain to be established.
Newton, C., Newton, C
core  

Preclinical and Clinical Experience with Cisplatin Resistance

Hematology/Oncology Clinics of North America, 1995
Despite the general lack of clinical evidence supporting the preclinical data, there have been many attempts to overcome cisplatin resistance in clinical situations. These efforts have focused on both the proposed mechanisms of resistance as well as novel approaches to renew efficacy.
J L, Marshall, P A, Andrews
openaire   +2 more sources

Metabolic vulnerability of cisplatin‐resistant cancers [PDF]

The EMBO Journal, 2018
Cisplatin is the most widely used chemotherapeutic agent, and resistance of neoplastic cells against this cytoxicant poses a major problem in clinical oncology. Here, we explored potential metabolic vulnerabilities of cisplatin-resistant non-small human cell lung cancer and ovarian cancer cell lines.
Florine Obrist, Judith Michels, Sylvere Durand, Alexis Chery, Jonathan Pol, Sarah Levesque, Adrien Joseph, Valentina Astesana, Federico Pietrocola, Gen Sheng Wu, Maria Castedo, Guido Kroemer   +11 more
openaire   +2 more sources